Exploring Treatment for Non-Immune Neurotoxicity Syndromes in CAR T-Cell Patients

In this week's episode, we’ll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences in glycosylation affect the clearance of human plasma-derived and recombinant von Willebrand factor concentrates.

Featured Articles:

• Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome
• Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
• Enhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF